Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen
NCT ID: NCT00791973
Last Updated: 2014-07-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
15 participants
INTERVENTIONAL
2008-11-30
2010-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms
NCT01007253
Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms
NCT00891436
Nasal Ocular Reflexes Contribute to Eye Symptoms
NCT00117832
Intranasal Steroids and the Nasal Ocular Response
NCT00473915
A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis
NCT01279057
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Veramyst, then Placebo
fluticasone furoate (Veramyst) nasal spray once daily for a week, then one week washout period followed by placebo nasal spray once daily for a week
fluticasone furoate
2 puffs in each nostril once daily for 1 week
Placebo
2 puffs in each nostril once daily for 1 week
Placebo, then Veramyst
placebo nasal spray once daily for a week, then one week washout period followed by fluticasone furoate (veramyst) nasal spray once daily for a week
fluticasone furoate
2 puffs in each nostril once daily for 1 week
Placebo
2 puffs in each nostril once daily for 1 week
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fluticasone furoate
2 puffs in each nostril once daily for 1 week
Placebo
2 puffs in each nostril once daily for 1 week
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. History of grass and/or ragweed allergic rhinitis.
3. Positive skin test to grass and/or ragweed antigen.
4. Positive response to screening nasal challenge.
Exclusion Criteria
2. Pregnant or lactating women.
3. Upper respiratory infection within 14 days of study start.
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
University of Chicago
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Robert Naclerio
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Naclerio, MD
Role: PRINCIPAL_INVESTIGATOR
University of Chicago
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Chicago Medical Center
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16367B (OC 3)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.